Lisata Therapeutics, Inc.

Novo Nordisk A/S

Quotes on Lisata Therapeutics, a pharmaceutical company developing therapies to combat tumors, <a href="https://finance.yahoo.com/quote/LSTA/">gained</a> more than 10% yesterday, April 15, after it announced a partnership with one of the largest industry manufacturers, Catalent, to evaluate the efficacy of a promising Lisata therapy. Since December, Catalent has been owned by Novo Holdings, the controlling shareholder of Denmark’s Novo Nordisk, a global leader in weight-loss medications.

Biotech small cap Lisata Therapeutics jumps 10% on partnership with Novo subsidiary


Quotes on the small-cap MAIA Biotechnology <a href="https://www.marketwatch.com/investing/stock/maia/analystestimates?mod=mw_quote_tab&amp;utm_source=in_materials">jumped</a> almost 6% yesterday, Tuesday, February 4, after the company <a href="https://ir.maiabiotech.com/news-events/press-releases/detail/124/maia-biotechnology-announces-positive-efficacy-updates-for?utm_source=in_materials">revealed</a> phase II clinical trial results for its drug that is said to offer a fundamentally new approach to cancer treatment. The therapy has proved to be superior to existing treatments, MAIA claims, and the chances of U.S. regulatory approval are "stronger than ever." 

Biotech small cap MAIA jumps on positive trial data for its cancer drug

<a href="https://www.who.int/ru/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services?utm_source=in_materials#:~:text=%D0%B1%D1%8B%D0%BB%20%D1%80%D0%B0%D0%BA%20%D0%BB%D0%B5%D0%B3%D0%BA%D0%B8%D1%85%20(1%2C8,%D1%81%D0%BC%D0%B5%D1%80%D1%82%D0%B8%2C%206%2C8%25).">According</a> to the World Health Organization, one in five people worldwide develops some form of cancer in their lifetime. While certain cancers respond well to treatment, others manage to "shield" themselves from targeted therapies. The micro-cap company MAIA Biotechnology is developing a drug to "trick" cancer cells, infiltrate them, and destroy them from within. As for the investment opportunity, MAIA shares are <a href="https://www.channelchek.com/news-channel/maia-biotechnology-maia-maia-announces-supply-agreement-for-second-phase-2-trial-with-three-new-indications?utm_source=in_materials">valued</a> as having 600% upside by the investment firm Noble Capital Markets.

Outsmarting cancer: Why immune-oncology firm MAIA has 600% upside

Shares of micro-cap company GeoVax, which specializes in cancer treatments and vaccines, rose nearly 7% on Wednesday, January 15. The company announced "significant progress" in early testing of its cancer drug for head and neck cancer and confirmed plans to move to the next phase of clinical trials. Analysts see upside of nearly 550% for GeoVax, which is also developing a monkeypox vaccine.

Cancer therapy and vaccine maker GeoVax gains on progress in cancer drug trials

Quotes on MAIA Biotechnology shares jumped 6.4% in U.S. premarket trading today, Tuesday, December 17, following a 10.0% surge the previous day. This came after the company announced that the FDA had <a href="https://ir.maiabiotech.com/news-events/press-releases/detail/120/maia-biotechnology-granted-fda-rare-pediatric-disease?utm_source=in_materials">granted</a> a special designation to its drug for pediatric brain tumors. The designation <a href="https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs?utm_source=in_materials">came with</a> a voucher that can be redeemed to receive priority review for another drug or sold for hundreds of millions of dollars.

MAIA soars after its cancer drug receives FDA 'rare pediatric disease' designation

Shares of CNS Pharmaceuticals, a developer of treatments for brain cancer, surged more than 22% at the opening of trading on Monday. This follows a roughly 23% drop on Friday, June 14, when the company <a href="https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-announces-pricing-of-registered-direct-offering-and-concurrent-private-placement-39339608">announced</a> an agreement with private investors to sell $1.37 million worth of shares.

#Oncology: 6

Biotech small cap Lisata Therapeutics jumps 10% on partnership with Novo subsidiary

Biotech small cap MAIA jumps on positive trial data for its cancer drug

Outsmarting cancer: Why immune-oncology firm MAIA has 600% upside

Cancer therapy and vaccine maker GeoVax gains on progress in cancer drug trials

MAIA soars after its cancer drug receives FDA 'rare pediatric disease' designation

Shares of brain cancer therapy developer surge by 22%